Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Renal impairment in a rural African antiretroviral programme
BMC Infectious Diseases, Volume 9, Article 143, Year 2009
Notification
URL copied to clipboard!
Description
Background: There is little knowledge regarding the prevalence and nature of renal impairment in African populations initiating antiretroviral treatment, nor evidence to inform the most cost effective methods of screening for renal impairment. With the increasing availability of the potentially nephrotixic drug, tenofovir, such information is important for the planning of antiretroviral programmes. Methods: (i) Retrospective review of the prevalence and risk factors for impaired renal function in 2189 individuals initiating antiretroviral treatment in a rural African setting between 2004 and 2007 (ii) A prospective study of 149 consecutive patients initiating antiretrovirals to assess the utility of urine analysis for the detection of impaired renal function. Severe renal and moderately impaired renal function were defined as an estimated GFR of ≤ 30 mls/min/1.73 m2 and 30-60 mls/min/1.73 m2 respectively. Logistic regression was used to determine odds ratio (OR) of significantly impaired renal function (combining severe and moderate impairment). Co-variates for analysis were age, sex and CD4 count at initiation. Results: (i) There was a low prevalence of severe renal impairment (29/2189, 1.3% 95% C.I. 0.8-1.8) whereas moderate renal impairment was more frequent (287/2189, 13.1% 95% C.I. 11.6-14.5) with many patients having advanced immunosuppression at treatment initiation (median CD4 120 cells/μl). In multivariable logistic regression age over 40 (aOR 4.65, 95% C.I. 3.54-6.1), male gender (aOR 1.89, 95% C.I. 1.39-2.56) and CD4<100 cells/ul (aOR 1.4, 95% C.I. 1.07-1.82) were associated with risk of significant renal impairment (ii) In 149 consecutive patients, urine analysis had poor sensitivity and specificity for detecting impaired renal function. Conclusion: In this rural African setting, significant renal impairment is uncommon in patients initiating antiretrovirals. Urine analysis alone may be inadequate for identification of those with impaired renal function where resources for biochemistry are limited. © 2009 Franey et al; licensee BioMed Central Ltd.
Authors & Co-Authors
Franey, Cara
South Africa, Durban
University of Kwazulu-natal
Knott, Deborah
South Africa, Hlabisa
Hlabisa Hospital
Bärnighausen, Till Winfried
South Africa, Durban
University of Kwazulu-natal
United States, Chapel Hill
School of Public Health
Dedicoat, Martin John
South Africa, Empangeni
Ngwelezana Hospital
Adam, Ahmed
South Africa, Hlabisa
Hlabisa Hospital
Lessells, Richard John
South Africa, Durban
University of Kwazulu-natal
Newell, Marie Louise
South Africa, Durban
University of Kwazulu-natal
United Kingdom, London
Ucl Great Ormond Street Institute of Child Health
Cooke, Graham S.
South Africa, Durban
University of Kwazulu-natal
United Kingdom, London
Imperial College London
Statistics
Citations: 32
Authors: 8
Affiliations: 6
Identifiers
Doi:
10.1186/1471-2334-9-143
e-ISSN:
14712334
Study Design
Cross Sectional Study
Cohort Study
Case-Control Study
Participants Gender
Male